Adicet Bio Appoints Julie Maltzman, MD, as Chief Medical Officer

Chartwell Partners is pleased to have worked with gamma delta T cell therapy company, Adicet Bio, to recruit Julie Maltzman, MD, as Chief Medical Officer. She joins Adicet from IconOVir Bio where she served as Chief Medical Officer leading, designing, and executing on a clinical development program focused on refractory solid tumors. Prior to that, she served as the VP, Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech. There, Dr. Maltzman oversaw the successful worldwide registration and commercialization of the solid tumor blockbuster combination therapy Tecentriq+Avastin® and co-led the cross-functional team accountable for managing all Tecentriq® program activities including manufacturing, safety, biomarker and translational research, regulatory strategy, branding and positioning. Dr. Maltzman also served as the executive Co-Chair of their multifunctional, senior-level integrated Cancer Immunotherapy Committee (CITC) which brought together all key functions to articulate an integrated Roche Group Cancer Immunotherapy Strategic roadmap.

Dr. Maltzman led early First-In-Human trials for rheumatoid arthritis with novel monoclonal antibodies while at Morphotek Inc. With additional leadership roles at flagship biopharma companies including Gilead and Glaxo SmithKline, Dr. Maltzman has designed and efficiently implemented clinical studies exceeding enrollment goals months earlier than anticipated, assisted with CMC (Chemistry, Manufacturing and Controls) initiatives to support clinical and regulatory submissions, conceptualized and negotiated multiple US and EU labels, and established and built Medical and Medical Affairs functions including activating key opinion leader and scientific educational initiatives to drive therapeutic awareness and adoption.

Dr. Maltzman earned her MD from the University of Colorado, completed her Internship and Residency in the Department of Internal Medicine at the University of Chicago, and completed a Fellowship in the Division of Hematology/Oncology at the University of Pennsylvania.